Application of CD45 as biomarker in screening effectiveness and accuracy of CD26 antibody or derivative thereof in tumor treatment
The invention provides application of CD45 as a biomarker in screening effectiveness of a subject on tumor treatment of a CD26 antibody or a derivative thereof. Specifically, when the CD45 does not express or is low in expression, it is judged that the treatment of the subject receiving the CD26 ant...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Patent |
| Sprache: | chi ; eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | GE CHENNAN HANG JIANHUA MA YONG CAO PEIPEI |
| description | The invention provides application of CD45 as a biomarker in screening effectiveness of a subject on tumor treatment of a CD26 antibody or a derivative thereof. Specifically, when the CD45 does not express or is low in expression, it is judged that the treatment of the subject receiving the CD26 antibody or the derivative thereof is effective or the effective probability is high, and when the CD45 is high in expression or relatively high in expression, it is judged that the treatment of the subject receiving the CD26 antibody or the derivative thereof is ineffective or the ineffective probability is high. A biomarker capable of effectively screening the tumor treatment effectiveness of the CD26 antibody or the derivative thereof is screened out, the tumor treatment accuracy and effectiveness of the CD26 antibody or the derivative thereof can be remarkably improved, and the clinical benefit of a patient is improved; a new mechanism of treatment effectiveness and accuracy of the CD26 serving as a new target spo |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN118541167A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN118541167A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN118541167A3</originalsourceid><addsrcrecordid>eNqNjbEOwjAQQ7swIOAfjg9gCLTAWhUQExN7dU0vcKJNouRaiZUvJwg-gMmS_WxPs1fpfccahZ0FZ6A65AVghIZdj-FBAdhC1IHIsr0BGUNaeCRLMQLaFlDrIaB-fsvrbTKFG9cmI0BLgUf88CB3CpSYNCdDnzIJhNKTlXk2MdhFWvx0li1Px2t1XpF3NUWPOr1JXV2U2he5UttdufmHeQMH4Uj0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Application of CD45 as biomarker in screening effectiveness and accuracy of CD26 antibody or derivative thereof in tumor treatment</title><source>esp@cenet</source><creator>GE CHENNAN ; HANG JIANHUA ; MA YONG ; CAO PEIPEI</creator><creatorcontrib>GE CHENNAN ; HANG JIANHUA ; MA YONG ; CAO PEIPEI</creatorcontrib><description>The invention provides application of CD45 as a biomarker in screening effectiveness of a subject on tumor treatment of a CD26 antibody or a derivative thereof. Specifically, when the CD45 does not express or is low in expression, it is judged that the treatment of the subject receiving the CD26 antibody or the derivative thereof is effective or the effective probability is high, and when the CD45 is high in expression or relatively high in expression, it is judged that the treatment of the subject receiving the CD26 antibody or the derivative thereof is ineffective or the ineffective probability is high. A biomarker capable of effectively screening the tumor treatment effectiveness of the CD26 antibody or the derivative thereof is screened out, the tumor treatment accuracy and effectiveness of the CD26 antibody or the derivative thereof can be remarkably improved, and the clinical benefit of a patient is improved; a new mechanism of treatment effectiveness and accuracy of the CD26 serving as a new target spo</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240823&DB=EPODOC&CC=CN&NR=118541167A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,309,781,886,25569,76552</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240823&DB=EPODOC&CC=CN&NR=118541167A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>GE CHENNAN</creatorcontrib><creatorcontrib>HANG JIANHUA</creatorcontrib><creatorcontrib>MA YONG</creatorcontrib><creatorcontrib>CAO PEIPEI</creatorcontrib><title>Application of CD45 as biomarker in screening effectiveness and accuracy of CD26 antibody or derivative thereof in tumor treatment</title><description>The invention provides application of CD45 as a biomarker in screening effectiveness of a subject on tumor treatment of a CD26 antibody or a derivative thereof. Specifically, when the CD45 does not express or is low in expression, it is judged that the treatment of the subject receiving the CD26 antibody or the derivative thereof is effective or the effective probability is high, and when the CD45 is high in expression or relatively high in expression, it is judged that the treatment of the subject receiving the CD26 antibody or the derivative thereof is ineffective or the ineffective probability is high. A biomarker capable of effectively screening the tumor treatment effectiveness of the CD26 antibody or the derivative thereof is screened out, the tumor treatment accuracy and effectiveness of the CD26 antibody or the derivative thereof can be remarkably improved, and the clinical benefit of a patient is improved; a new mechanism of treatment effectiveness and accuracy of the CD26 serving as a new target spo</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjbEOwjAQQ7swIOAfjg9gCLTAWhUQExN7dU0vcKJNouRaiZUvJwg-gMmS_WxPs1fpfccahZ0FZ6A65AVghIZdj-FBAdhC1IHIsr0BGUNaeCRLMQLaFlDrIaB-fsvrbTKFG9cmI0BLgUf88CB3CpSYNCdDnzIJhNKTlXk2MdhFWvx0li1Px2t1XpF3NUWPOr1JXV2U2he5UttdufmHeQMH4Uj0</recordid><startdate>20240823</startdate><enddate>20240823</enddate><creator>GE CHENNAN</creator><creator>HANG JIANHUA</creator><creator>MA YONG</creator><creator>CAO PEIPEI</creator><scope>EVB</scope></search><sort><creationdate>20240823</creationdate><title>Application of CD45 as biomarker in screening effectiveness and accuracy of CD26 antibody or derivative thereof in tumor treatment</title><author>GE CHENNAN ; HANG JIANHUA ; MA YONG ; CAO PEIPEI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN118541167A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>GE CHENNAN</creatorcontrib><creatorcontrib>HANG JIANHUA</creatorcontrib><creatorcontrib>MA YONG</creatorcontrib><creatorcontrib>CAO PEIPEI</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>GE CHENNAN</au><au>HANG JIANHUA</au><au>MA YONG</au><au>CAO PEIPEI</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Application of CD45 as biomarker in screening effectiveness and accuracy of CD26 antibody or derivative thereof in tumor treatment</title><date>2024-08-23</date><risdate>2024</risdate><abstract>The invention provides application of CD45 as a biomarker in screening effectiveness of a subject on tumor treatment of a CD26 antibody or a derivative thereof. Specifically, when the CD45 does not express or is low in expression, it is judged that the treatment of the subject receiving the CD26 antibody or the derivative thereof is effective or the effective probability is high, and when the CD45 is high in expression or relatively high in expression, it is judged that the treatment of the subject receiving the CD26 antibody or the derivative thereof is ineffective or the ineffective probability is high. A biomarker capable of effectively screening the tumor treatment effectiveness of the CD26 antibody or the derivative thereof is screened out, the tumor treatment accuracy and effectiveness of the CD26 antibody or the derivative thereof can be remarkably improved, and the clinical benefit of a patient is improved; a new mechanism of treatment effectiveness and accuracy of the CD26 serving as a new target spo</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | chi ; eng |
| recordid | cdi_epo_espacenet_CN118541167A |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | Application of CD45 as biomarker in screening effectiveness and accuracy of CD26 antibody or derivative thereof in tumor treatment |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-11T14%3A57%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=GE%20CHENNAN&rft.date=2024-08-23&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN118541167A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |